Amisulpride is under clinical development by Sunovion Pharmaceuticals and currently in Phase III for Bipolar Disorder (Manic Depression). According to GlobalData, Phase III drugs for Bipolar Disorder (Manic Depression) have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Amisulpride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amisulpride (SEP-4199) is under development for the treatment of major depressive episodes associated with bipolar depression. The drug candidate is administered through oral route as a tablet. the drug candidate act by targeting 5-hydroxytryptamine receptor 7 (5 HT7), Dopamine receptors D2/D3.
Sunovion Pharmaceuticals overview
Sunovion Pharmaceuticals (Sunovion), a subsidiary of Sumitomo Dainippon Pharmaceutical Co Ltd, is a research-based pharmaceutical company. It discovers, develops, and marketize therapeutic products that focus on the treatment of the central nervous system and respiratory disorders. Its major products include eslicarbazepine acetate tablets, lurasidone HCl tablets, eszopiclone tablets, glycopyrrolate inhalation solution and levalbuterol tartrate inhalation aerosol. The company’s product candidates are intended for the treatment of schizophrenia, neuropathic pain, bipolar depression, treatment-resistant depression, agitation in Alzheimer’s disease, and Parkinson’s disease, among others. It has partnerships with various pharmaceutical companies such as Psychogenics and others. Sunovion is headquartered in Marlborough, Massachusetts, the US.
For a complete picture of Amisulpride’s drug-specific PTSR and LoA scores, buy the report here.